CRYO-CELL INTERNATIONAL, INC. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
CRYO-CELL INTERNATIONAL, INC. (CCEL) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of $188.27 thousand for the 6-month period ending 2026-05-31, per its 10-Q filed 2026-07-15.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2026-07-15
- CRYO-CELL INTERNATIONAL, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2026-02-28 was -$69.36K.
- CRYO-CELL INTERNATIONAL, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2025-02-28 was -$337.84K.
- CRYO-CELL INTERNATIONAL, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2024-02-29 was -$158.96K.
- CRYO-CELL INTERNATIONAL, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2023-02-28 was -$330.86K.
- CRYO-CELL INTERNATIONAL, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2025 was -$241.93K, a 256.19% decline from fiscal 2024.
- CRYO-CELL INTERNATIONAL, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2024 was $154.89K.
- CRYO-CELL INTERNATIONAL, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2023 was -$1.30M.
- CRYO-CELL INTERNATIONAL, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2022 was -$6.56M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2026-05-31 | $188.27K 10-Q · filed 2026-07-15 | |||
| 2026-02-28 | -$69.36K 10-Q · filed 2026-04-14 | |||
| 2025-11-30 | -$241.93K 10-K · filed 2026-02-27 | |||
| 2025-08-31 | -$295.75K 10-Q · filed 2025-10-15 | |||
| 2025-05-31 | -$423.47K 10-Q · filed 2026-07-15 | |||
| 2025-02-28 | -$337.84K 10-Q · filed 2026-04-14 | |||
| 2024-11-30 | $154.89K 10-K · filed 2026-02-27 | |||
| 2024-08-31 | -$208.63K 10-Q · filed 2025-10-15 | |||
| 2024-05-31 | $63.13K 10-Q · filed 2025-07-15 | |||
| 2024-02-29 | -$158.96K 10-Q · filed 2025-04-14 | |||
| 2023-11-30 | -$1.30M 10-K · filed 2025-02-28 | |||
| 2023-08-31 | -$1.12M 10-Q · filed 2024-10-15 | |||
| 2023-05-31 | -$579.96K 10-Q · filed 2024-07-15 | |||
| 2023-02-28 | -$330.86K 10-Q · filed 2024-04-15 | |||
| 2022-11-30 | -$6.56M 10-K · filed 2024-02-28 | |||
| 2022-08-31 | -$5.34M 10-Q · filed 2023-10-12 | |||
| 2022-05-31 | -$5.46M 10-Q · filed 2023-07-14 | |||
| 2022-02-28 | -$6.12M 10-Q · filed 2023-04-21 | |||
| 2021-11-30 | -$2.10M 10-K · filed 2023-02-28 | |||
| 2021-08-31 | -$2.66M 10-Q · filed 2022-10-18 | |||
| 2021-05-31 | -$2.41M 10-Q · filed 2022-07-11 | |||
| 2021-02-28 | $916.69K 10-Q · filed 2022-04-13 | |||
| 2020-11-30 | $3.82M 10-K · filed 2022-02-22 | |||
| 2020-08-31 | $1.57M 10-Q · filed 2021-10-15 | |||
| 2020-05-31 | $1.88M 10-Q · filed 2021-07-15 | |||
| 2020-02-29 | $1.87M 10-Q · filed 2021-04-14 | |||
| 2019-11-30 | $501.00K 10-K · filed 2021-03-01 | |||
| 2019-08-31 | $1.30M 10-Q · filed 2020-10-15 | |||
| 2019-05-31 | $428.55K 10-Q · filed 2020-07-10 | |||
| 2019-02-28 | $1.04M 10-Q · filed 2020-04-14 | |||
| 2018-11-30 | -$239.12K 10-K · filed 2020-02-28 | |||
| 2018-08-31 | $760.82K 10-Q · filed 2019-10-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MANGOCEUTICALS, INC. (MGRX) | United States | $0.010B | -0.43 |
| BioRestorative Therapies, Inc. (BRTX) | United States | $0.064B | |
| Park Dental Partners, Inc. (PARK) | United States | $0.094B | |
| VIEMED HEALTHCARE, INC. (VMD) | United States | $0.336B | 29.92 |
| agilon health, inc. (AGL) | United States | $1.272B | -7.76 |
| Progyny, Inc. (PGNY) | United States | $1.994B | 28.37 |
| Sotera Health Co (SHC) | United States | $5.271B | 30.96 |
| DAVITA INC. (DVA) | United States | $11.147B | 16.80 |